Skip to main content

Astria Therapeutics, Inc.

ATXSDelisted Jan 23, 2026
Industry
Pharmaceutical Preparations
SEC CIK
0001454789

Astria Therapeutics, Inc. was delisted on Jan 23, 2026; its insiders filed their last Form 4 on Jan 23, 2026; 141 institutions reported holding it in 13F filings for Q4 2025, worth $738.2M in total; Soros Fund Management was the only superinvestor holding it.

Q3 2022 vs. Q2 2022

How the institutions holding Astria Therapeutics, Inc. changed between Q2 2022 and Q3 2022.

All holders in Q3 2022All holders in Q2 2022

13F holders of ATXS: Q2 2022 compared with Q3 2022
MeasureQ2 2022Q3 2022Change
Holders3043+13
Shares5.73M9.83M+4.10M (+71.5%)
Value$17.2M$88.8M+$71.7M (+416.7%)

New holders (15)

Institutions that held Astria Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.

Institutions new to ATXS in Q3 2022
InstitutionSharesValue% of portfolio
Vivo Capital, LLC1,000,000$9.04M1.00%
Driehaus Capital Management LLC656,361$5.93M0.09%
Tri Locum Partners LP631,579$5.71M1.63%
Ghost Tree Capital, LLC500,000$4.52M1.85%
Altium Capital Management LP445,000$4.02M1.51%
Affinity Asset Advisors, LLC400,043$3.62M1.67%
Opaleye Management Inc.133,500$1.21M0.50%
State Street Corp29,082$263.0K0.00%
Jane Street Group, LLC21,498$194.0K0.00%
Dimensional Fund Advisors LP17,521$158.0K0.00%
Cubist Systematic Strategies, LLC14,666$133.0K0.00%
Jump Financial, LLC12,000$108.0K0.00%
Acadian Asset Management LLC11,461$103.0K0.00%
JPMorgan Chase & Co299$3.00K0.00%
BNP Paribas Arbitrage, SA119$1.08K0.00%

Sold out (2)

Institutions that held Astria Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.

Institutions that sold out of ATXS in Q3 2022
InstitutionShares, Q2 2022Value, Q2 2022
Ra Capital Management, L.P.760,857$2.28M
Simplex Trading, LLC77$0